Market capitalization | $826.97m |
Enterprise Value | $583.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 20.28 |
EV/Sales (TTM) EV/Sales | 2.90 |
P/S ratio (TTM) P/S ratio | 4.11 |
P/B ratio (TTM) P/B ratio | 2.16 |
Revenue growth (TTM) Revenue growth | 9.88% |
Revenue (TTM) Revenue | $201.21m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a Cytek BioSciences Inc forecast:
6 Analysts have issued a Cytek BioSciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 201 201 |
10%
10%
|
|
Gross Profit | 111 111 |
4%
4%
|
|
EBITDA | -13 -13 |
27%
27%
|
EBIT (Operating Income) EBIT | -24 -24 |
7%
7%
|
Net Profit | -10 -10 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.
Head office | United States |
CEO | Wen Jiang |
Employees | 676 |
Founded | 1992 |
Website | cytekbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.